Kadcyla 100mg Injection

About Kadcyla 100mg Injection

Kadcyla 100mg Injection contains Ado-Trastuzumab Emtansine (T-DM1), a targeted anticancer medication used to treat HER2-positive breast cancer in adults. It is prescribed for patients with early-stage or advanced breast cancer that has spread to other parts of the body, as well as for those who have residual disease or cancer recurrence after previous HER2-targeted therapy and chemotherapy. Kadcyla combines two powerful components: Trastuzumab, a monoclonal antibody that specifically targets HER2-positive cancer cells, and Emtansine, a chemotherapy agent that destroys cancer cells from within. By delivering chemotherapy directly to HER2-positive cells, Kadcyla helps slow cancer growth while minimizing damage to healthy tissues. Patients with residual breast cancer following chemotherapy often face a higher risk of recurrence, making targeted therapies such as Kadcyla an important treatment option. Common side effects may include nausea, vomiting, diarrhea, fatigue, headache, and hair thinning, while serious side effects such as allergic reactions, unusual bleeding, liver problems, or infusion-related reactions require immediate medical attention. Although kidney-related side effects are uncommon, regular monitoring of overall health and treatment response is essential during therapy. Kadcyla 100mg Injection plays a significant role in the management of HER2-positive breast cancer by helping improve disease control, reduce the risk of recurrence, and enhance long-term treatment outcomes.